Vectors Without Borders: building a global viral vector CDMO
November 4, 2026
How do you build a global viral vector manufacturing network that can support cell and gene therapy developers from early development through to commercial supply?
OXB Chief Business Officer Sébastien Ribault discusses OXB’s evolution into a global viral vector CDMO and the expansion of its manufacturing capabilities across the UK, US and France.
The article explores:
- The expansion of OXB global viral vector development and manufacturing network.
- Strategies to accelerate timelines for lentiviral vector and AAV programmes.
- How OXB supports programmes through late-stage development, GMP manufacturing and commercial supply.
- The importance of consistent capabilities and expertise across a global manufacturing network.
- How more than 30 years of viral vector experience, data and innovation can help inform future programmes.
- OXB’s continued investment in innovation, including in vivo cell and gene therapies.
Discover how OXB is combining global capabilities, scientific expertise and manufacturing experience to support the evolving needs of cell and gene therapy developers.
About our contributing expert
Sébastien Ribault, Chief Business Officer
Dr. Sébastien Ribault joined OXB in November 2022 as Chief Commercial Officer and became Chief Business Officer on 1 September 2024. He has over 25 years of experience across the biotechnology industry and CDMO space. Dr. Ribault was previously at Merck Life Sciences where he was Vice President & Head of Biologics and Viral Vector CDMO, leading Merck’s CDMO Expansion project, establishing the Services business case and helping to establish the Life Science Services business unit.
Prior to his 17 years with Merck KGaA, Dr. Ribault was a Gene Therapy Development Scientist at Transgene and Head of the R&D Laboratory at Hemosystem. He has a PhD in Molecular and Cellular Biology from the University of Strasbourg.